On Friday, the UK Medicines Control Agency approved the one-dose Johnson & Johnson COVID-19 vaccine.
The vaccine is only approved for people over the age of 18, and pregnant or breastfeeding women must make their own decisions after consulting with healthcare professionals.
Following Pfizer-BioNTech, Oxford-AstraZeneca, and Moderna vaccines, this is the fourth vaccine approved in the UK to combat COVID-19, a disease caused by the CCP (Chinese Communist Party) virus, also known as novel coronavirus.
The Medicines and Healthcare products Regulatory Agency (MHRA) stated that the vaccine met all of the required safety, quality, and effectiveness standards.
“We conducted a thorough review of Janssen’s conditional marketing authorization application, including information on quality, safety, and effectiveness.” I am delighted to confirm today that this authorization has been granted, “said MHRA Chief Executive Dr. June Raine in a statement on Friday.
The MHRA, according to Raine, is “constantly monitoring all COVID-19 vaccines in use once they have been approved to ensure that the benefits of protecting people against the disease continue to outweigh any risks.”
Janssen is a Johnson & Johnson pharmaceutical subsidiary that developed the COVID-19 vaccine, also known as Ad26.COV2.S.
The vaccine should be available in the UK by the end of the year.
The United Kingdom has ordered 20 million doses of the vaccine, which England’s Deputy Chief Medical Officer Jonathan Van-Tam previously stated could be used for difficult-to-reach populations where recalling them for a second jab is not always successful.
The vaccine can be stored at normal refrigerator temperatures, allowing it to be distributed in places such as nursing homes.
The MHRA is thought to have delayed early approval of the vaccine due to concerns raised in the US about a link to extremely rare blood clots.
Belgium suspended the use of the Johnson & Johnson vaccine for people under the age of 41 on Wednesday, following the death of a woman from severe side effects after receiving the shot.
On April 20, the European Medicines Agency stated that there is a “possible link” between Johnson & Johnson’s COVID-19 vaccine and some cases of blood clots, but the cases are “very rare” and “unusual,” and the benefits outweigh the risks.
The vaccine was previously suspended in the United States, but it was lifted on April 23 after the Centers for Disease Control and Prevention’s (CDC) vaccine advisory committee determined that the benefits outweighed the risks.